A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis - PubMed (original) (raw)

Review

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis

Surosree Ganguli et al. Hepat Med. 2019.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the West. Non-alcoholic steatohepatitis (NASH) is the progressive form of NAFLD and can lead to cirrhosis, hepatocellular carcinoma, and is associated with increased cardiovascular risks. Multiple components and risk factors are thought to be involved in the pathogenesis of NAFLD and NASH. Optimal therapy has not yet been found, but many advances have been made with the discovery of potential therapeutic options. In this paper, we aim to provide a comprehensive review of approved, studied, and upcoming treatment options for NAFLD and NASH. Non-pharmacologic therapy (lifestyle modifications and bariatric surgery) and pharmacologic therapy are both reviewed. Pharmacologic therapy target components thought to be involved in the pathogenesis of this disease process including insulin resistance, oxidative stress, inflammation, lipid metabolism, and fibrosis are reviewed in this paper. Results of the emerging treatment targets in phase 2 and 3 clinical trials are also included.

Keywords: NAFLD; NASH; cirrhosis; obesity; treatment.

© 2019 Ganguli et al.

PubMed Disclaimer

Conflict of interest statement

Dr Sanjaya K Satapathy reports grants from Gilead, Intercept, Shire, Allergan, Bayer, Conatus, Exact Sciences, Dova, Biotest, and Genfit, served on the Speakers Bureau for Alexion, Intercept, and Dova, and served on the Advisory board for Gilead, Bayer, and Dova, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–1395. doi: 10.1002/hep.20466 - DOI - PubMed
    1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690. doi: 10.1038/nrgastro.2013.171 - DOI - PubMed
    1. Fan JG. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis. 2008;9:63–67. doi: 10.1111/j.1751-2980.2008.00323.x - DOI - PubMed
    1. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51:373–375. doi: 10.1002/hep.23521 - DOI - PMC - PubMed
    1. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi: 10.1016/j.metabol.2015.12.012 - DOI - PubMed

Publication types

LinkOut - more resources